A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Trial Profile

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Nervous system neoplasms; Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms STARTRK-NG
  • Sponsors Ignyta; Roche
  • Most Recent Events

    • 14 Jun 2018 Planned End Date changed from 1 Mar 2019 to 31 Mar 2019.
    • 14 Jun 2018 Planned primary completion date changed from 1 Sep 2018 to 30 Sep 2018.
    • 05 Jun 2018 Results (n=16) of dose-escalation phase, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top